Selected transactions

Exclusive Financial Advisor to Mesotherapy leader Suisselle in the structuring of the strategic partnership for the licensing of their novel skinbooster “Cellbooster” to Chinese partner Sihuan Pharmaceuticals.

Outlicensing of the global rights to the Italian range of Dermocosmetics to DermaForce (the Skinbetter Science Division) for an undisclosed double-digit upfront payment, royalties and milestones.

Exclusive Financial Advisor to BMG Pharma to enter a Distribution, Supply and Licensing Agreement covering a range of Oral-Care brands with Pierre Fabre Médicament.

Exclusive Financial Advisor to Croma in the structuring of the strategic partnership for the manufacturing and supply of Menarini-Relife’s lead dermal filler Range Definisse.

Exclusive Financial Advisor to Croma in constructing a 70-30% US- based exit JV to be majority- led by Korean Toxin specialist Hugel Corporation and concurrent Divestiture of its Canadian and Australian Subsidiaries to Hugel.

Exclusive Financial Advisor to Bloomage for the completion of a strategic partnership including the investment in a minority equity ownership and entry into a long- term licensing agreement.

Supply Agreement for two BMG original oral and dental hygiene products: Aftacure Gel and Aftacure Spray.

Exclusive Financial Advisor to Universkin for the completion of a strategic distribution agreement with Croma-Pharma GmbH and divestiture of a 5% stake to Croma.

Exclusive advisor to Vaxon Biotech on a global collaboration partnership, including a call option arrangement an upfront and several clinical performance milestones with a major US oncology player.

Acquisition of global rights to the Belgian Biotech Ablynx’s nanobody technology platform, global licensing agreement across several therapeutic areas.